# Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

> **NCT05982990** · PHASE1 · UNKNOWN · sponsor: **Respirent Pharmaceuticals Co Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
- **DRUG:** ADVAIR DISKUS® 250/50

## Key facts

- **NCT ID:** NCT05982990
- **Lead sponsor:** Respirent Pharmaceuticals Co Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-01
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-11-20
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2023-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05982990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05982990, "Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05982990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*